When Kevin Lobo was promoted to the top spot at Stryker Corporation, he moved up from being head of the company’s orthopedics business. On November 8, David Floyd, the former head of DePuy Orthopaedics was named to fill the role of group president, Orthopaedics for Stryker.
Lobo Lands Floyd at Stryker
2 min read Premium comments
Floyd – Orthopedics and Spine
Lobo also shuffled around responsibilities of his senior managers to give Floyd the added responsibility for the company’s spine business.
The spine business was previously assigned to group president of MedSurg and Spine, Tim Scannell.
Scannell – Neurotechnology and MedSurg
So here’s Lobo’s new line-up. Scannell will continue to head up the company’s MedSurg division and take over the Neurotechnology business, which includes the Neurovascular division and Craniomaxillofacial business. Floyd will be in charge of Orthopaedics, which includes Reconstructive, Trauma, Extremities, Joint Preservation, Orthobiologics and Performance Solutions, and Spine. Both men will report to Lobo.
“This realignment will best leverage our leadership talent to drive growth in our Reconstructive, MedSurg and Neurotechnology and Spine segments, ” said Lobo.
“David brings a strong medical device and orthopedic perspective to Stryker through his successful leadership roles in a broad range of enterprises, including a venture backed startup, middle market med tech and large cap multinationals. He is a proven leader who has demonstrated the ability to drive profitable growth through innovation and we are delighted to have David join our executive team at Stryker, ” said Lobo. Floyd, said a company statement, has successfully managed global businesses through unprecedented industry change while maintaining strong company, regulatory and customer relationships.
He joins Stryker after 25 years in the medical technology and orthopedics industry where he held a number of senior level leadership roles at DePuy, a division of Johnson and Johnson, Abbott Spine, AxioMed Spine, Centerpulse Orthopaedics and most recently as CEO for OrthoWorx in Warsaw, Indiana.
Scannell began his career with Stryker in 1990 and held various leadership positions within the Endoscopy, Biotech, and Spine divisions before being named group president in 2008.
Lobo and his two key lieutenants make up a streamlined chain of command. From everything we know about these men, it should be a pretty smooth transition.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.